Aclarubicin hydrochloride

This classification denotes an aclacinomycin antibiotic with the molecular formula C42H53NO15.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 501948RI66, chemically known as 1-naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-o-(2,6-dideoxy-4-o-((2r-trans)-tetrahydro-6-methyl-5-oxo-2h-pyran-2-yl)-alpha-l-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-l-lyxo-hexopyranosyl)oxy)-, methyl ester, hydrochloride, (1r-(1alpha,2beta,4beta))- but more generally known as aclarubicin hydrochloride, which bears US NIH Compound Identifier 153751. The base compound, Aclarubicin, arises in both base and hydrochloride forms. European Medicines Agency schedules Aclarubicin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00285MIG. Most nations, for tariff and trade purposes, schedule aclarubicin hydrochloride under HS 29419000. As of Q4 2014, ACLARUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Aclarubicin hydrochloride bears US NLM identifiers UMLS ID C0591033 and NCI Concept Code C95830. SMILES: CC[C@]1(C[C@@H](C2C(CC3C(C2O)C(=O)C4C(CCCC4O)C3=O)[C@H]1C(=O)OC)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O.CL.